Atrial fibrillation (AF)

Diagnostic and therapeutic approach

  1. Diagnosis
  2. Treatment
  3. Scores
  4. Pharmaceuticals
  5. ESC recommandations

Pharmaceuticals

  1. Amiodarone
  2. Oral anticoagulants
  3. ß-Blockers
  4. Dabigatran (Pradaxa)
  5. Digitalis (Digoxine)
  6. Diltiazem (Dilzem)
  7. Dronedarone (Multaq)
  8. Flecainide (Tambocor)
  9. Ibutilide (Corvert)
  10. Propafenone (Rytmonorm)
  11. Rivaroxaban (Xarelto)
  12. Sotalol (Sotalex)
  13. Verapamil (Isoptin)
  14. Vernakalant (Brinavess)
  15. Apixaban (Eliquis)
  16. Edoxaban (Lixiana)

Vernakalant (Brinavess)

(Brinavess)

Available only in injectable

Bolus

3 mg/kg of body weight in 10 minutes.

If no conversion after 15 minutes, add 2mg/kg in 10 minutes.

Contra-indications

  • Hypersensitivity to vernakalant hydrochloride (Brinavess) or to any of the excipients.
  • Hemodynamic instability.
  • Acute or chronic heart failure of NYHA class III or IV.
  • Severe aortic stenosis.
  • Systolic blood pressure <100 mmHg.
  • QT interval prolongation.
  • Severe bradycardia, sinus node dysfunction.
  • AV block of 2nd and 3rd degree.
  • Administration of intravenous antiarrhythmics (class I and class III) within 4 hours before or after administration of vernakalant (Brinavess).
  • Acute Coronary Syndrome.

http://www.drugs.com/international/vernakalant.html